Florfenicol in vitro activities for a total of 756 bacterial isolates from respiratory tract infections of cattle and swine were comparatively investigated by the agar diffusion method and the microdilution broth method. Florfenicol showed high in vitro activity against Pasteurella multocida, Mannheimia haemolytica, Actinobacillus pleuropneumoniae, and Streptococcus suis, with all of the isolates inhibited by <2 g of florfenicol per ml.
Florfenicol (FFC), a fluorinated chloramphenicol derivative, is exclusively used in veterinary medicine. So far, its use in food-producing animals-exclusive of aquaculture-has been limited to cattle and swine. FFC was licensed as an injectable drug only for the treatment of bovine and porcine respiratory tract infections in 1995 and 2000, respectively. The main target bacteria in cattle are Pasteurella multocida, Mannheimia haemolytica, and Haemophilus somnus, whereas those in pigs are P. multocida, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, and Streptococcus suis. The aim of this study was to monitor the in vitro susceptibilities to FFC of bovine respiratory pathogens at 5 to 6 years after the introduction of FFC and those of porcine respiratory pathogens at the time of introduction of FFC into clinical veterinary use.
For this study, we collected a total of 756 bacterial isolates from respiratory tract infections of cattle and swine in Germany during the years 2000 and 2001. The bacteria included in this study comprised 122 P. multocida and 118 M. haemolytica isolates of bovine origin as well as 212 P. multocida, 45 A. pleuropneumoniae, 160 B. bronchiseptica, and 99 S. suis isolates of porcine origin. All isolates originated from nasal swabs or lung tissue of diseased animals and were collected on the basis of one isolate per herd. Nasal swabs were taken by veterinarians and sent to diagnostic laboratories. Lung tissue samples were obtained during necropsy at the diagnostic laboratories. Microbiological sample processing and biochemical confirmation of the species assignment followed standard procedures (4) . All bacterial isolates were investigated (for their in vitro susceptibilities to FFC only) by two different methods: (a) the disk diffusion method, with disks containing 30 g of FFC (Becton Dickinson, Heidelberg, Germany), and (b) the microdilution broth method, with microtiter plates (Sensititre, Westlake, Ohio) that contained FFC concentrations of 0.12 to 128 g/ml in serial twofold dilutions. Performance and evaluation of the susceptibility tests followed the recommendations given in documents M31-A (8) and M31-A2 (9) of the National Committee for Clinical Laboratory Standards. The three reference strains Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213, and A. pleuropneumoniae ATCC 27090 were used for quality control purposes (6, 8, 9) .
The currently available approved FFC-specific breakpoints (9) are only valid for P. multocida, M. haemolytica, and H. somnus isolates from cattle. Breakpoints for susceptibility are a zone diameter of Ն19 mm and a drug MIC of Յ2 g/ml (9). Based on these breakpoints, all bovine P. multocida and M. haemolytica isolates included in this study proved to be suscep- (5) showed that all S. suis isolates from swine (n ϭ 110) and from humans (n ϭ 25) were susceptible to FFC; however, no MIC data or zone diameters were provided. The MICs for B. bronchiseptica isolates from 2000 and 2001 were (in general) higher than those for the other porcine pathogens (Table 2) . A total of nine independent isolates for which the FFC MICs were 16 or 32 g/ml were detected. PCR assays for the genes floR (1), cmlA (11) , and cfr (10) confirmed that none of these genes was present in any of the nine B. bronchiseptica isolates.
In conclusion, continuous monitoring of in vitro susceptibilities to FFC is an essential requirement for the determination of the actual susceptibility status and for the early recognition of potential resistance developments among bacterial pathogens involved in respiratory tract infections of cattle and swine. Based on the low MICs seen in the present and earlier studies, no resistance development has been documented in P. multocida, M. haemolytica, A. pleuropneumoniae, and S. suis isolates from bovine and porcine respiratory tract infections since the introduction of FFC into veterinary use. 
